Results 101 to 110 of about 23,832 (234)

Materials

open access: yes, 1995
SIGLEAvailable from British Library Document Supply Centre- DSC:OP-95/C / BLDSC - British Library Document Supply CentreGBUnited ...
Office of Science and Technology, London (United Kingdom)   +1 more
core  

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

open access: yesMolecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder   +10 more
wiley   +1 more source

Printing materials Science and technology

open access: yes, 1998
SIGLEAvailable from British Library Document Supply Centre-DSC:98/33518 / BLDSC - British Library Document Supply CentreGBUnited ...
Pira International, Leatherhead (United Kingdom)   +1 more
core  

Insights into the addition of exogenous materials to enhance anaerobic digestion

open access: yes
Anaerobic digestion (AD) is a globally recognized technology for treating organic waste, providing key environmental benefits, including renewable energy generation. Over the years, significant research efforts have focused on optimizing AD under diverse
Toka Mahmoud Farhat   +5 more
core   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

open access: yesMolecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi   +14 more
wiley   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

open access: yesMolecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka   +9 more
wiley   +1 more source

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

open access: yesMolecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu   +13 more
wiley   +1 more source

Foresight in business Materials advantage

open access: yes, 1998
Available from British Library Document Supply Centre-DSC:GPE/3493 / BLDSC - British Library Document Supply CentreSIGLEGBUnited ...
Office of Science and Technology, London (United Kingdom)
core  

Tumor B‐cell infiltration in platinum‐treated advanced muscle‐invasive urothelial carcinoma

open access: yesMolecular Oncology, EarlyView.
Bladder tumors with higher pretreatment memory B‐cell infiltration were linked to longer survival after cisplatin chemotherapy, but not carboplatin. These tumors also showed more organized immune structures (tertiary lymphoid structures) and a shared pro‐inflammatory B‐cell‐rich community, suggesting that memory B cells may help identify patients most ...
Konrad Stawiski   +10 more
wiley   +1 more source

Atomic Building Blocks of Global Buildings. [PDF]

open access: yesEnviron Sci Technol
Broyles JM   +3 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy